Compare Stocks: OMER, GRFS, ACAD, and PBLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.69 -4.3%	$27.16	$19.69 ▼ $30.96	$4.77B	0.86	1.65 million shs	923,897 shs
GRFS Grifols	$7.85 +0.3%	$7.66	$6.96 ▼ $10.23	$5.34B	0.67	644,002 shs	373,619 shs
OMER Omeros	$18.99 +0.7%	$13.14	$3.94 ▼ $19.65	$1.37B	2.6	1.70 million shs	764,822 shs
PBLS Parabilis Medicines	$40.15 +0.1%	$33.63	$24.51 ▼ $41.49	$4.96B	N/A	561,848 shs	183,167 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.14%	-2.20%	+12.96%	+33.23%	+12.61%
GRFS Grifols	+1.29%	-0.89%	-0.38%	+3.30%	-19.11%
OMER Omeros	+0.59%	+3.51%	+50.16%	+84.00%	+339.63%
PBLS Parabilis Medicines	+1.62%	+2.17%	+18.11%	+4,010,999,900.00%	+4,010,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$27.69 -4.3%	$27.16	$19.69 ▼ $30.96	$4.77B	0.86	1.65 million shs	923,897 shs
GRFS Grifols	$7.85 +0.3%	$7.66	$6.96 ▼ $10.23	$5.34B	0.67	644,002 shs	373,619 shs
OMER Omeros	$18.99 +0.7%	$13.14	$3.94 ▼ $19.65	$1.37B	2.6	1.70 million shs	764,822 shs
PBLS Parabilis Medicines	$40.15 +0.1%	$33.63	$24.51 ▼ $41.49	$4.96B	N/A	561,848 shs	183,167 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.14%	-2.20%	+12.96%	+33.23%	+12.61%
GRFS Grifols	+1.29%	-0.89%	-0.38%	+3.30%	-19.11%
OMER Omeros	+0.59%	+3.51%	+50.16%	+84.00%	+339.63%
PBLS Parabilis Medicines	+1.62%	+2.17%	+18.11%	+4,010,999,900.00%	+4,010,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	24.09% Upside
GRFS Grifols	1.67	Reduce	$10.00	27.39% Upside
OMER Omeros	2.67	Moderate Buy	$38.00	100.11% Upside
PBLS Parabilis Medicines	3.00	Buy	$41.67	3.78% Upside

Current Analyst Ratings Breakdown

Latest OMER, GRFS, ACAD, and PBLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$27.00 ➝ $28.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/17/2026	GRFS Grifols	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $39.00
8/6/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.45	$0.85 per share	32.57	$7.58 per share	3.65
GRFS Grifols	$8.51B	0.63	$1.44 per share	5.46	$13.63 per share	0.58
OMER Omeros	N/A	N/A	$1.90 per share	10.02	($0.71) per share	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	12.47	28.26	21.54	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
GRFS Grifols	$454.82M	$0.19	41.32	5.99	0.28	5.54%	6.21%	2.39%	11/10/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	14.84	16.81	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest OMER, GRFS, ACAD, and PBLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/13/2026	Q2 2026	PBLS Parabilis Medicines	-$0.16	-$2.32	-$2.16	-$2.32	N/A	$0.15 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.09	1.15%	N/A	47.37%	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Latest OMER, GRFS, ACAD, and PBLS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/19/2026	GRFS Grifols	special	$0.0945		7/2/2026	7/2/2026	7/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
GRFS Grifols	1.10	2.37	0.81
OMER Omeros	N/A	1.95	1.94
PBLS Parabilis Medicines	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
GRFS Grifols	N/A
OMER Omeros	48.79%
PBLS Parabilis Medicines	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
GRFS Grifols	0.19%
OMER Omeros	10.50%
PBLS Parabilis Medicines	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable
OMER Omeros	210	72.39 million	64.79 million	Optionable
PBLS Parabilis Medicines	N/A	123.53 million	N/A	N/A

OMER, GRFS, ACAD, and PBLS Headlines

Recent News About These Companies

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1 at 7:00 AM | globenewswire.com

ICONIQ Capital LLC Takes $9.58 Million Position in Parabilis Medicines, Inc. $PBLS

August 31 at 6:32 AM | marketbeat.com

Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS

August 29, 2026 | marketbeat.com

1,600,937 Shares in Parabilis Medicines, Inc. $PBLS Purchased by General Catalyst Group Management LLC

August 28, 2026 | marketbeat.com

venBio Partners LLC Purchases Shares of 5,266,697 Parabilis Medicines, Inc. $PBLS

August 28, 2026 | marketbeat.com

Jupiter Topco LLC Buys Shares of 2,296,547 Parabilis Medicines, Inc. $PBLS

August 28, 2026 | marketbeat.com

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Rating of "Buy" by Analysts

August 26, 2026 | marketbeat.com

ARCH Venture Management LLC Makes New $175.52 Billion Investment in Parabilis Medicines, Inc. $PBLS

August 26, 2026 | marketbeat.com

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

August 25, 2026 | markets.businessinsider.com

Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.

August 25, 2026 | globenewswire.com

ICONIQ Capital LLC Makes New Investment in Parabilis Medicines, Inc. $PBLS

August 24, 2026 | marketbeat.com

Éléments financiers clés - PBLS

August 23, 2026 | fr.investing.com

Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9% - Here's What Happened

August 18, 2026 | marketbeat.com

Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS

August 18, 2026 | marketbeat.com

Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year High - What's Next?

August 17, 2026 | marketbeat.com

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform

August 14, 2026 | seekingalpha.com

Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell

August 13, 2026 | finance.yahoo.com

Parabilis Medicines: Q2 Earnings Snapshot

August 13, 2026 | finance.yahoo.com

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026 | globenewswire.com

Parabilis Medicines (NASDAQ:PBLS) Reaches New 1-Year High - What's Next?

August 10, 2026 | marketbeat.com

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

July 6, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OMER, GRFS, ACAD, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$27.69 -1.24 (-4.29%)

As of 03:39 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Grifols NASDAQ:GRFS

$7.85 +0.02 (+0.26%)

As of 03:38 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Omeros NASDAQ:OMER

$18.99 +0.13 (+0.69%)

As of 03:39 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Parabilis Medicines NASDAQ:PBLS

$40.15 +0.04 (+0.10%)

As of 03:38 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OMER, GRFS, ACAD, and PBLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OMER, GRFS, ACAD, and PBLS Earnings

Compare Dividends

Latest OMER, GRFS, ACAD, and PBLS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OMER, GRFS, ACAD, and PBLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OMER, GRFS, ACAD, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Grifols NASDAQ:GRFS

Omeros NASDAQ:OMER

Parabilis Medicines NASDAQ:PBLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools